| Abstract|| |
Background: Multiple viral warts represent a frustrating challenge for both patients and physicians. Management is difficult, primarily due to recalcitrance to standard therapy and high recurrence rates. Recently, intralesional antigen immunotherapy has shown promising efficacy in the treatment of warts. Objective: The aim of our study was to compare efficacy and safety of intralesional PPD versus measles, mumps, and rubella (MMR) vaccine in the management of multiple warts. Materials and Methods: One hundred and five patients having multiple warts were randomly divided into group A (PPD), group B (MMR) and group C (normal saline), with 35 patients in each group. In each group, the largest wart was injected intralesionally with 0.1 mL of vaccine at 2 weeks interval until complete clearance or for a maximum of 8 weeks. Results: Out of 105 patients enrolled in the study, 27, 25, and 21 patients completed the study in group A, group B, and group C, respectively. Rest were lost to follow up due to various reasons such as pain and long treatment duration. Complete clearance was seen in 14 patients (51.85%) in group A, 14 patients (56%) in group B, and 0 patients in group C. Partial clearance was seen in four patients (14.81%) in group A, four patients (16%) in group B, and three (14.28%) patients in group C. Nine patients (33.33%) in group A, seven patients (28%) in group B and 18 (85.71%) patients in group C did not respond to immunotherapy. Conclusions: Intralesional immunotherapy by both vaccines is a promising, effective, and safe treatment modality with MMR having slight edge.
Keywords: Immunotherapy, MMR, PPD, vaccine, viral warts
|How to cite this article:|
Bhalala KB, Poojary S, Shah KS. Comparative study of efficacy of intralesional purified protein derivative (PPD) versus intralesional measles, mumps, and rubella (MMR) vaccine in management of multiple viral warts. J Cutan Aesthet Surg 2021;14:397-403
|How to cite this URL:|
Bhalala KB, Poojary S, Shah KS. Comparative study of efficacy of intralesional purified protein derivative (PPD) versus intralesional measles, mumps, and rubella (MMR) vaccine in management of multiple viral warts. J Cutan Aesthet Surg [serial online] 2021 [cited 2022 Jul 5];14:397-403. Available from: https://www.jcasonline.com/text.asp?2021/14/4/397/337595
| Introduction|| |
Verrucae are cutaneous papillomas caused by human papilloma virus (HPV), a double stranded DNA non-enveloped virus of the Papovaviridae family. Till date, more than 200 subtypes of HPV have been classified in literature. Types of warts include common warts (verrucae vulgaris), genital warts (condyloma accuminata), flat warts (plane wart), and palmoplantar warts.
Treatment modalities of warts include cytodestructive methods such as topical application of podophyllin, salicylic acid, trichloroacetic acid, imiquimod, cryotherapy, electrocautery, carbon dioxide laser, and surgical excision. Adverse effects of these methods include severe pain, scarring, and dyspigmentation. Most of these methods are ineffective in prevention of recurrence of warts.
Recently, intralesional immunotherapy has been used in the treatment of different types of warts. Various antigens such as Trichophyton, Candida, Mycobacterium welchii, Bacillus Calmette-Guerin (BCG), purified protein derivative (PPD), measles, mumps, and rubella (MMR) have been used with varying results.
Considering the paucity of studies on immunotherapy, especially head-to-head comparison studies of different modes of immunotherapy in the treatment of warts, we conducted a study to compare the efficacy of intralesional PPD and MMR vaccine in the treatment of multiple viral warts and their long-term safety.
Aims and objectives
The objective was to determine the efficacy and safety of intralesional PPD in comparison with intralesional MMR vaccine and a control (normal saline) in the management of multiple viral warts.
Clinically diagnosed cases of warts (>1 in number) of all ages and both genders who consented for the study were included.
The exclusion criteria are as follows:
- Known history of hypersensitivity to PPD/MMR vaccine
- Pregnancy and lactation
- Immunocompromised status
- Local site infection/ulceration.
| Materials and Methods|| |
This was a single blind, randomized, controlled trial conducted over a period of 1 year at a tertiary healthcare center. After obtaining institutional Ethics Committee approval, trial was registered in the Clinical Trial Registry-India (CTRI registration number: CTRI/2018/02/012019).
A total of 105 patients fulfilling the inclusion criteria were included in the study. They were randomized using a computer-generated random number table and equally divided into three groups: group A included 35 patients who received intralesional PPD vaccine, group B included 35 patients who received intralesional MMR vaccine, and group C included 35 patients who received intralesional normal saline. They were advised not to use any other treatment modality during the study period of 8 weeks.
Demographic and clinical data of all patients were recorded, including duration of warts, past history, treatment history, type of warts, and site and number of warts before the first injection. Photographs were taken before each injection for documentation of regression in size and number of warts, appearance of new lesions, and side effects.
Group A received 0.1 mL intralesional PPD vaccine (Akray Pharma, Gujarat, India), group B received 0.1 mL intralesional reconstituted MMR vaccine (Tresivac, Serum Institute of India, Pune, India), and group C received 0.1 mL intralesional normal saline as a control group, in the mother wart (largest wart) with the help of an insulin syringe. In all the groups, intralesional injections were given at an interval of 2 weeks till complete clearance of all warts (both treated and distant site) or for a maximum of four treatment sessions. The patients were followed up monthly for the next 6 months after completion of treatment for clinical assessment of any long-term side effects and recurrence.
Response was evaluated as follows: (1) complete clearance which indicated 100% resolution of all warts (both treated and distant site) and normalization of dermatoglyphics in case of palmoplantar warts, (2) partial clearance which meant 50–99% resolution, and (3) no response which meant less than 50% resolution of warts.
Data were entered into the Microsoft Excel sheet and was analyzed using SPSS software (Version 23.0. Armonk, NY, USA). Data were expressed as mean and standard deviation for quantitative variables and as number and percentage for qualitative variables. ANOVA and χ2 test were used for comparison. P-value less than 0.05 was considered significant.
| Observations and Results|| |
Out of the 105 patients enrolled, 73 patients completed the study. The baseline clinical characteristics of all the groups are presented in [Table 1]. Eight patients in group A, 10 patients in group B and 14 patients in group C dropped out of the study. Reasons for dropout included lack of improvement, side effects such as pain, swelling, and flu-like symptoms.
Therapeutic response and its statistical comparison in three groups are presented in [Table 2] and [Table 3], respectively. Comparing the therapeutic response of group A (PPD) with control group C (normal saline) and group B (MMR) with control group C, P-value was significant (<0.001) but it was not significant on comparing group A with group B (P = 0.917). Clinical response of various types of warts to group A, B and C immunotherapy at the end of 8 weeks is depicted in [Table 4][Table 5][Table 6], respectively [Figure 1][Figure 2][Figure 3][Figure 4][Figure 5]. The mean numbers of treatment sessions for complete clearance of lesions in PPD-treated group were 3.85 sessions and in MMR-treated group were 3.71 sessions. None of the patients in group C had complete clearance.
|Table 4: Therapeutic response in various types of warts at the end of 8 weeks of intralesional PPD therapy|
Click here to view
|Table 5: Therapeutic response in various types of warts at the end of 8 weeks of intralesional MMR therapy|
Click here to view
|Table 6: Therapeutic response in various types of warts at the end of 8 weeks of intralesional normal saline therapy|
Click here to view
|Figure 1: A and B show the baseline and complete clearance of plantar warts with three sessions of PPD vaccine|
Click here to view
|Figure 2: A and B show the baseline and complete clearance of subungual warts with four sessions of PPD vaccine|
Click here to view
|Figure 3: A–D show the baseline and complete clearance of filiform wart and common warts with four sessions of PPD vaccine|
Click here to view
|Figure 4: A and B show the baseline and complete clearance of palmar warts with four sessions of MMR vaccine|
Click here to view
|Figure 5: A and B show the baseline and partial clearance of common warts with four sessions of MMR vaccine|
Click here to view
The most common side effect reported was pain during injection (100% patients). One patient developed scarring and one patient developed swelling at the injection site in group A (PPD) [Figure 6]. Three patients in group B (MMR) developed flu-like symptoms within 2 days of the injection. Recurrence was observed in one patient in group A (PPD) and no recurrence was noted in group B (MMR) in the follow-up period of 6 months.
|Figure 6: A and B show scarring and swelling at injection site respectively in patient treated with PPD vaccine|
Click here to view
| Discussion|| |
Treatment of cutaneous warts includes various topical/local and systemic therapies. These treatment modalities are often associated with side effects such as scarring, hyperpigmentation, and high recurrence rate. Intralesional immunotherapy with various antigens such as mumps, Candida, Trichophyton, MMR vaccine, and PPD vaccine has shown promising therapeutic results for warts with better safety, lesser side effects, and a lower recurrence rate. It also has an added advantage of clearance of both treated and distant site lesions.,
The exact mechanism of intralesional immunotherapy is still unknown. Intralesional immunotherapy enhances the ability of the immune system to identify certain antigens such as bacteria, fungi, and virus that induce delayed type of hypersensitivity (DTH). DTH leads to increase proliferation of macrophages and releases Th1 cytokines such as IL-2, IL-4, IL-5, IL-8, TNF-α, and INF γ. The Th1 cytokines activate cytotoxic T cells and natural killer cells and destroy the HPV.
Our study showed highly significant therapeutic response with MMR and PPD, respectively, in comparison with the control group. On comparison of MMR and PPD, the therapeutic response was slightly better with MMR; however, the difference was not statistically significant. Combination of three antigens in MMR vaccine produces better immunostimulant effect than PPD vaccine alone, which is responsible for slight better response with MMR vaccine.
The therapeutic response seen in our study was slightly higher than that in studies by Kus et al., Clifton et al., Essa et al., King et al., and Signore et al. and lower than that in studies by Nimbalkar et al., Saoji et al., Nofal et al., Gupta et al., and Gamil et al. [Table 7].,,,,,,,, The difference in study population, duration, types of warts, and number of treatment sessions may also be responsible for this variation in therapeutic response among various studies. Percentage of complete clearance observed in our study is lower than that reported in a similar comparative study by Shaheen et al. The higher therapeutic response in Shaheen et al. was explained by the fact that only those patients who demonstrated positive intradermal tests to the specific antigen were recruited in the study.
The average number of treatment sessions required for complete clearance of both treated and distant lesions in the PPD-treated group was 3.85 and in the MMR-treated group was 3.71, which is less than that reported by Johnson et al. (4.7 sessions), Na et al. (5.38 sessions), and Horn et al. (5.8 sessions).,,
The most common side effect noted was pain (100% patients) during injection which resolved within 1–2 h without any intervention. Scarring and swelling were noted in one patient (2.85%) each in PPD-treated group. Three patients (8.5%) in the MMR-treated group developed flu-like symptoms within 2 days of the injection in contrast to 6% patients in a study by Awal et al. and 13.6% patients in a study by Johnson., No serious side effects such as infection, wounding, redness, severe pruritus, and alopecia at the injection site were observed in our study in contrast to previous studies.,,,,
Limitations of our study are as follows: (1) This was a single-blind study with a relatively small sample size. (2) Pre-treatment intradermal test (Mantoux test) was not done in our study, which could have helped to include patients with expected better response to immunotherapy. (3) All types of viral warts were included in the study. The number of cases of each type of viral wart was relatively small. Hence, it was not possible to study the comparative efficacy of MMR and PPD in each individual variant. (4) The maximum number of injections given was four. Better therapeutic response could possibly have been obtained by increasing the number of treatment sessions as reported by Gupta et al., showing 88.9% cure rate with 10 injections of killed M. welchii vaccine. Larger comparative studies would be required to determine whether more number of injections would result in a better therapeutic response.
| Conclusion|| |
Intralesional immunotherapy using either PPD vaccine or MMR vaccine shows comparable efficacy and safety in the treatment of warts. Immunotherapy is a highly effective, low-cost treatment option with good tolerability. It showed good complete clearance at both treated and distant site lesions. Because of less side effects and low recurrence rate when compared with traditional treatment modalities, intralesional immunotherapy with PPD or MMR can be recommended as a first-line treatment option for multiple warts and recalcitrant warts.
The authors thank Dr Jimish Bagadia, Dr Saurabh Jaiswal, and Dr Suby Arora for their continuous guidance and enormous help in smooth conduction of the study. The authors also thank Dr Mihir Rupani and Dr Khushali Parikh, Bhavnagar Medical College, Gujarat for helping in statistical analysis of the study.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H Classification of papillomaviruses. Virology 2004;324:17-27.
Nofal A, Nofal E Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol 2010;24:1166-70.
Signore RJ Candida albicans
intralesional injection immunotherapy of warts. Cutis 2002;70:185-92.
Nimbalkar A, Pande S, Sharma R, Borkar M Tuberculin purified protein derivative immunotherapy in the treatment of viral warts. Indian J Drugs Dermatol 2016;2:19-23
Bacelieri R, Johnson SM Cutaneous warts: An evidence-based approach to therapy. Am Fam Physician 2005;72:647-52.
Gupta S, Malhotra AK, Verma KK, Sharma VK Intralesional immunotherapy with killed mycobacterium w vaccine for the treatment of ano-genital warts: An open label pilot study. J Eur Acad Dermatol Venereol 2008;22:1089-93.
Kus S, Ergun T, Gun D, Akin O Intralesional tuberculin for treatment of refractory warts. J Eur Acad Dermatol Venereol 2005;19:515-6.
Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida
antigens. Pediatr Dermatol 2003;20:268-71.
Eassa BI, Abou-Bakr AA, El-Khalawany MA Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther 2011;24:137-43.
King M, Johnson SM, Horn TD Intralesional immunotherapy for genital warts. Arch Dermatol 2005;141:1606-7.
Saoji V, Lade NR, Gadegone R, Bhat A Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial. Indian J Dermatol Venereol Leprol 2016;82:42-6.
Gamil H, Elgharib I, Nofal A, Abd-Elaziz T Intralesional immunotherapy of plantar warts: Report of a new antigen combination. J Am Acad Dermatol 2010;63:40-3.
Shaheen MA, Salem SA, Fouad DA, El-Fatah AA Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther 2015;28:194-200.
Johnson SM, Horn TD Intralesional immunotherapy for warts using a combination of skin test antigens: A safe and effective therapy. J Drugs Dermatol 2004;3:263-5.
Na CH, Choi H, Song SH, Kim MS, Shin BS Two-year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for warts. Clin Exp Dermatol 2014;39: 583-9.
Horn TD, Johnson SM, Helm RM, Roberson PK Intralesional immunotherapy of warts with mumps, Candida
, and Trichophyton
skin test antigens: A single-blinded, randomized, and controlled trial. Arch Dermatol 2005;141:589-94.
Awal G, Kaur S Therapeutic outcome of intralesional immunotherapy in cutaneous warts using the mumps, measles, and rubella vaccine: A randomized, placebo-controlled trial. J Clin Aesthet Dermatol 2018;11:15-20.
Johnson SM, Roberson PK, Horn TD Intralesional injection of mumps or candida skin test antigens: A novel immunotherapy for warts. Arch Dermatol 2001;137:451-5.
Lichon V, Khachemoune A Plantar warts: A focus on treatment modalities. Dermatol Nurs 2007;19:372-5.
Dasher DA, Burkhart CN, Morrell DS Immunotherapy for childhood warts. Pediatr Ann 2009;38:373-9.
Dr. Shital Poojary
Department of Dermatology, Venereology and Leprology, K. J. Somaiya Medical College, OPD 26, 6th Floor, Everard Nagar, Sion Chunnabhatti, Mumbai 400022, Maharashtra.
Source of Support: None, Conflict of Interest: None
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]